SCHEMBL4256860

SCHEMBL4256860

COc1cccc(C(O)c2cc(Br)ccc2NC(=O)CCl)c1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 4/20 0.45
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 6/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
KDM4E B2RXH2 3/20 0.40
GAA P10253 3/20 0.40
LMNA P02545 3/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
ALDH1A1 P00352 3/20 0.40
POLB P06746 2/20 0.40
PKM P14618 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
BLM P54132 1/20 0.40
RECQL P46063 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MITF O75030 1/20 0.39
THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4193257 0.76 ALDH1A1 (0.55) LPAR1MEN1KMT2AMAPTNPC1
SCHEMBL3981602 0.75 ALDH1A1 (0.48) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL29428945 0.75 BRD4 (0.53) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL22312086 0.75 BRD4 (0.53) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL4109691 0.74 ALDH1A1 (0.43) LPAR1MEN1KMT2AMAPTKDM4E
SCHEMBL4112243 0.74 TAS1R3 (0.44) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL8560596 0.73 LPAR1 (0.47) LPAR1MEN1KMT2AMAPTNPC1
SCHEMBL8567301 0.73 LPAR1 (0.47) LPAR1MEN1KMT2AMAPTNPC1
SCHEMBL8566775 0.73 LPAR1 (0.47) LPAR1MEN1KMT2AMAPTNPC1
SCHEMBL30613338 0.72 LPAR1 (0.47) LPAR1MEN1KMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598237-B2 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators WYETH (US) 2009-10-06 US disclosed
US-20080139530-A1 7-Aryl 1,5-Dihydro-4,1-Benzoxazepin-2(3H)-One Derivatives And Their Use As Progesterone Receptor Modulators WYETH (US) 2008-06-12 US disclosed
US-20080113964-A1 7-Aryl 1,5-Dihydro-4,1-Benzoxazepin-2(3H)-One Derivatives and Their Use As Progesterone Receptor Modulators WYETH (US) 2008-05-15 US disclosed
US-7323455-B2 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators WYETH (US) 2008-01-29 US disclosed
WO-2005095366-A1 7-ARYL 1,5-DIHYDRO-4,1-BENZOXAZEPIN-2(3H)-ONE DERIVATIVES AND THEIR USE AS PROGESTERONE RECEPTOR MODULATORS WYETH (US) 2005-10-13 WO disclosed
US-20050215539-A1 7-aryl 1,5-dihydro-4, 1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators WYETH (US) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113964-A1 7-Aryl 1,5-Dihydro-4,1-Benzoxazepin-2(3H)-One Derivatives and Their Use As Progesterone Receptor Modulators PGR, GPER1, PGRMC2 LPAR1 377/4885MEN1 3838/4885KMT2A 1610/4885
US-20080139530-A1 7-Aryl 1,5-Dihydro-4,1-Benzoxazepin-2(3H)-One Derivatives And Their Use As Progesterone Receptor Modulators PGR, GPER1, PGRMC2 LPAR1 377/4885MEN1 3838/4885KMT2A 1610/4885
US-20050215539-A1 7-aryl 1,5-dihydro-4, 1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators PGR, GPER1, PGRMC2 LPAR1 377/4885MEN1 3838/4885KMT2A 1610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.